CN100379419C - 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物 - Google Patents

含有4,5-环氧吗啡喃衍生物的稳定的药物组合物 Download PDF

Info

Publication number
CN100379419C
CN100379419C CNB98801274XA CN98801274A CN100379419C CN 100379419 C CN100379419 C CN 100379419C CN B98801274X A CNB98801274X A CN B98801274XA CN 98801274 A CN98801274 A CN 98801274A CN 100379419 C CN100379419 C CN 100379419C
Authority
CN
China
Prior art keywords
group
carbon atoms
group containing
atom
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB98801274XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1237106A (zh
Inventor
花村伸幸
堀内保秀
吉井良二
青木孝夫
原三千雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of CN1237106A publication Critical patent/CN1237106A/zh
Application granted granted Critical
Publication of CN100379419C publication Critical patent/CN100379419C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
CNB98801274XA 1997-07-11 1998-07-10 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物 Expired - Lifetime CN100379419C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP186950/97 1997-07-11
JP18695097 1997-07-11

Publications (2)

Publication Number Publication Date
CN1237106A CN1237106A (zh) 1999-12-01
CN100379419C true CN100379419C (zh) 2008-04-09

Family

ID=16197570

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB98801274XA Expired - Lifetime CN100379419C (zh) 1997-07-11 1998-07-10 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物

Country Status (15)

Country Link
US (1) US6372755B2 (enExample)
EP (1) EP0948965B1 (enExample)
JP (3) JP3617055B2 (enExample)
KR (1) KR100514963B1 (enExample)
CN (1) CN100379419C (enExample)
AT (1) ATE268178T1 (enExample)
AU (1) AU740404B2 (enExample)
CA (1) CA2265767C (enExample)
DE (1) DE69824277T2 (enExample)
DK (1) DK0948965T3 (enExample)
ES (1) ES2217563T3 (enExample)
NO (1) NO318831B1 (enExample)
PT (1) PT948965E (enExample)
TW (1) TWI285644B (enExample)
WO (1) WO1999002158A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
SG90259A1 (en) * 2000-08-17 2002-07-23 Control Ox Oy Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
JP4880813B2 (ja) * 2000-10-26 2012-02-22 第一三共株式会社 外用消炎鎮痛剤組成物
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
JP4963670B2 (ja) * 2004-04-07 2012-06-27 レスベラトロル パートナーズ， エルエルシー 栄養補助サプリメントおよびそれを処理する方法
US8288362B2 (en) 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
WO2005110439A2 (en) * 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
US20080096967A1 (en) * 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
TWI286941B (en) * 2005-07-27 2007-09-21 Anagen Therapeutics Inc Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
PL2151241T3 (pl) * 2007-04-26 2012-08-31 Toray Industries Trwały stały preparat zawierający pochodną 4,5-epoksymorfinanową
ES2648037T3 (es) * 2007-05-21 2017-12-28 Toray Industries, Inc. Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral
CN101658489B (zh) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 一种盐酸纳美芬注射液及其制备方法
BRPI0920599B1 (pt) * 2008-10-24 2021-10-19 Toray Industries, Inc. Comprimido estável contendo um derivado de 4,5-epoximorfinano
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
AU2010255747B2 (en) * 2009-06-04 2014-03-13 Alk-Abello A/S Stabilised composition comprising at least one adrenergic compound
ES2933198T3 (es) 2010-10-21 2023-02-02 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para usar
JP5750278B2 (ja) * 2011-02-28 2015-07-15 東洋カプセル株式会社 カンデサルタンシレキセチルのカプセル充填用組成物
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
JP6247118B2 (ja) * 2014-03-05 2017-12-13 東海カプセル株式会社 カプセル充填組成物
CA2980097C (en) 2015-03-19 2019-10-29 Daiichi Sankyo Company, Limited Solid preparation containing colorant
EP3272345B1 (en) * 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Solid preparation containing antioxidant agent
JP5918894B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN119157840A (zh) 2016-07-29 2024-12-20 东丽株式会社 光稳定性提高的固体制剂
JP6131379B1 (ja) * 2016-12-28 2017-05-17 森下仁丹株式会社 ４，５−エポキシモルヒナン誘導体含有製剤
JP7153197B2 (ja) * 2017-03-31 2022-10-14 東レ株式会社 ナルフラフィンを含有する錠剤化された医薬組成物
AU2019229892B2 (en) 2018-03-08 2025-01-30 University Of Kansas Treatment of demyelinating diseases
KR102849723B1 (ko) 2018-07-30 2025-08-22 다이이찌 산쿄 가부시키가이샤 안정화제를 함유하는 의약품의 고형 제제
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
WO2020205735A1 (en) 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
EP4062973A4 (en) * 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015081A1 (en) * 1992-01-23 1993-08-05 Toray Industries, Inc. Morphinan derivative and medicinal use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2765694B2 (ja) * 1988-01-29 1998-06-18 日清バーディシェ株式会社 酸化感受性化合物の安定な組成物
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015081A1 (en) * 1992-01-23 1993-08-05 Toray Industries, Inc. Morphinan derivative and medicinal use

Also Published As

Publication number Publication date
JP3617055B2 (ja) 2005-02-02
DE69824277D1 (de) 2004-07-08
ES2217563T3 (es) 2004-11-01
JP3743449B2 (ja) 2006-02-08
CN1237106A (zh) 1999-12-01
NO318831B1 (no) 2005-05-09
AU740404B2 (en) 2001-11-01
KR100514963B1 (ko) 2005-09-15
CA2265767C (en) 2007-12-04
DK0948965T3 (da) 2004-07-05
US20010004637A1 (en) 2001-06-21
CA2265767A1 (en) 1999-01-21
ATE268178T1 (de) 2004-06-15
EP0948965B1 (en) 2004-06-02
JP2005247866A (ja) 2005-09-15
PT948965E (pt) 2004-08-31
NO991152D0 (no) 1999-03-10
DE69824277T2 (de) 2004-09-23
US6372755B2 (en) 2002-04-16
EP0948965A4 (en) 2002-10-16
KR20000068528A (ko) 2000-11-25
NO991152L (no) 1999-05-10
JP2005002123A (ja) 2005-01-06
TWI285644B (en) 2007-08-21
AU8128298A (en) 1999-02-08
WO1999002158A1 (fr) 1999-01-21
EP0948965A1 (en) 1999-10-13
JP4311369B2 (ja) 2009-08-12

Similar Documents

Publication Publication Date Title
CN100379419C (zh) 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物
JPWO1999002158A1 (ja) ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
US6458842B1 (en) Liquid pharmaceutical compositions comprising thyroid hormones
ES2402544T3 (es) Preparación pelicular rápidamente soluble
JP2005002123A5 (enExample)
RU2333745C2 (ru) Композиции с контролируемым высвобождением
KR20120092700A (ko) 덱시부프로펜 경피흡수형 수성겔 화합물
US7094414B2 (en) Famotidine injections
AU2015312672B2 (en) Tadalafil oral dispersible film and preparing method thereof
KR100440354B1 (ko) 티아가빈염산염함유약학적조성물및그제조방법
US6436977B1 (en) Dosing regimens for lasofoxifene
KR20050009983A (ko) 트라마돌의 서방성 제제
JP2007522223A (ja) 制御放出配合物
JPH1171269A (ja) 経口液体医薬製剤
KR100344198B1 (ko) 실데나필 시트레이트의 속효제형
US6818662B2 (en) Pharmaceutical composition
JPH085784B2 (ja) シロツプ剤
JP2816227B2 (ja) 抗潰瘍薬
KR100389671B1 (ko) 염산 테르비나핀을 함유하는 항진균제 외용 약제 조성물
WO2005110372A1 (en) Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
JP2003012559A (ja) 局所麻酔剤
JP2007008852A (ja) プラバスタチンを含有する水性製剤の安定化方法
KR20180003413A (ko) 오셀타미비어 함유 경구용 고형제제 및 그 제조방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20080409

CX01 Expiry of patent term